Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients,The Prostate

当前位置： X-MOL 学术 › Prostate › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients
The Prostate ( IF 2.6 ) Pub Date : 2021-09-15 , DOI: 10.1002/pros.24235
Benedikt Hoeh _{1,

2} , Christoph Würnschimmel _{2,

3} , Rocco S Flammia _{2,

4} , Benedikt Horlemann ₂ , Gabriele Sorce _{2,

5} , Francesco Chierigo _{2,

6} , Zhe Tian ₂ , Fred Saad ₂ , Markus Graefen ₃ , Michele Gallucci ₄ , Alberto Briganti ₅ , Carlo Terrone ₆ , Shahrokh F Shariat _{7,

8,

9,

10,

11,

12} , Derya Tilki _{3,

13} , Luis A Kluth ₁ , Philipp Mandel ₁ , Felix K H Chun ₁ , Pierre I Karakiewicz ₂

Affiliation

Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, Québec, Canada.
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza Rome University, Rome, Italy.
Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, Weill Cornell Medical College, New York, New York, USA.
Department of Urology, University of Texas Southwestern, Dallas, Texas, USA.
Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
Institute for Urology and Reproductive Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
Division of Urology, Department of Special Surger, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Over the last decade, multiple clinical trials demonstrated improved survival after chemotherapy for metastatic prostate cancer (mPCa). However, real-world data validating this effect within large-scale epidemiological data sets are scarce. We addressed this void.

中文翻译：